GB-0895

The deep integration of experimental verification aims to lead programmable biology into a new era. Under The terms of the agreement, the collaboration will combine The Generate Platform's advanced technology with Novartis' deep expertise and capabilities in target biology, biologics development and clinical development to accelerate the development of innovative therapies. Although the number of targets and areas of treatment involved in the collaboration are currently under wraps. Novartis has advanced a total of $65 million to Generate, of which $15 million is earmarked to increase its equity stake in Generate. In addition, Generate will receive more than $1 billion in milestone payments based on the progress of the partnership, with tiered royalty benefits. Before that, Generate had signed a collaboration agreement with Amgen in 2022 worth up to $1.9 billion to work together on five clinically targeted protein therapies. A year later, Amgen further expanded its collaboration with Generate to include research and development on a sixth target. Currently, Generate has built a rich research and development pipeline covering multiple disease areas such as immunology, oncology and infectious diseases. Two drug candidates, GB-0669 and GB-0895, have successfully entered the clinical stage. GB-0669 is a monoclonal antibody targeting the spike protein region of COVID-19, while GB-0895 is an anti-TSLP monoclonal antibody specifically designed for patients with severe asthma. In addition, the Generate pipeline includes bi-specific drugs for non-small cell lung cancer, CAR-T therapies for solid tumors, and as-yet-undisclosed ADC therapies. The company said it plans to move four to five new pipelines into clinical trials over the next two years. After divesting its Sandoz business in 2023, Novartis has fully transformed itself into a company focused on innovative drug development. Its strategy focuses on four core therapeutic areas: cardio-nephro-metabolism, immunology, neuroscience and oncology. At the technology platform level, Novartis not only continues to strengthen the traditional chemical and biological drug platforms, but also actively expands the New Modality (novel therapy) platform, covering multiple frontier areas such as RLT (radioligand therapy), gene and cell therapy, and xRNA therapy. In recent years, Novartis has actively implemented its new strategy through a series of deals. According to the statistics of the drug Intelligence network, since 2019 to the end of September this year, the total amount of Novartis BD transactions has exceeded $60 billion, and the total amount of transactions since this year alone has exceeded the $20 billion mark. From the field of disease, Novartis has carried out a key layout in the fields of tumor, immunization and kidney disease. In terms of drug types, Novartis has high hopes for emerging platforms, especially radiligand therapy, xRNA therapy and AI platforms. In the cardiovascular-nephro-metabolic area, Novartis has achieved significant results with the successful application of xRNA therapy. Leqvio, for example, has been approved and rapidly released in more than 70 countries since it was approved by the FDA in 2020. Novartis expects peak annual sales of up to $3 billion. Building on Leqvio's success, Novartis has made multiple investments and partnerships totaling nearly $6 billion in xRNA therapeutics over the past two years to further consolidate and expand its leading position in the field. In the field of oncology, although Novartis has not made significant breakthroughs in the field of PD-1 therapy and ADC, it has made remarkable achievements in the field of RLT (radioligand therapy, nuclear drug). At present, Novartis has two RLT products Lutathera and Pluvicto successfully launched and achieved rapid volume. Novartis believes that the unique advantages of RLT with significant efficacy and low side effects are vigorously layout in this field. In the past two years, it has entered into a number of mergers and acquisitions or cooperative transactions totaling nearly $7 billion to further expand its presence in the radiopharmaceutical field. New technologies have become a new bright spot in Novartis' performance growth. According to Novartis' Q2 2024 financial results, sales of its radiolandin therapy Pluvicto reached $345 million in the quarter, an increase of 44%. Sales of the small nucleic acid drug Leqvio reached $182 million, an increase of 134%. Although the market size of New Modality is still in its infancy, it has great potential and relatively little competition. With the continuous cultivation and investment in these frontier areas, Novartis is gradually building a leading position in the industry, which is expected to form a solid market monopoly position in the future and bring considerable revenue growth for Novartis.